Paper33560416
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
Barajas RF and 20 others. Neuro Oncol, 2021. Cited by 147 papers, by iCite.
Cite this record
ConductScience Library. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Papers, record 33560416. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33560416
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
- PubMed
- Publication types
- Consensus Statement, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Central Nervous System Neoplasms | Major topic |
| Lymphoma | Major topic |
| Humans | |
| Central Nervous System | |
| Magnetic Resonance Imaging | |
| Positron-Emission Tomography | |
| Reproducibility of Results |
Source PubMed
Grants11
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 CA220378 | NCI NIH HHS | United States | U01CA220378 | PubMed and NIH | NIH RePORTER |
| R21 NS082609 | NINDS NIH HHS | United States | R21NS082609 | PubMed and NIH | NIH RePORTER |
| L30 CA220897 | NCI NIH HHS | United States | L30CA220897 | PubMed | NIH RePORTER |
| R01 CA239462 | NCI NIH HHS | United States | R01CA239462 | PubMed | NIH RePORTER |
| P50 CA211015 | NCI NIH HHS | United States | P50CA211015 | PubMed and NIH | NIH RePORTER |
| R01 CA139083 | NCI NIH HHS | United States | R01CA139083 | PubMed and NIH | NIH RePORTER |
| R01 CA221938 | NCI NIH HHS | United States | R01CA221938 | PubMed and NIH | NIH RePORTER |
| EP-C-15-003 | EPA | United States | PubMed | PubMed | |
| K08 CA237809 | NCI NIH HHS | United States | K08CA237809 | PubMed and NIH | NIH RePORTER |
| R01 CA158079 | NCI NIH HHS | United States | R01CA158079 | PubMed | NIH RePORTER |
| R21 CA223757 | NCI NIH HHS | United States | R21CA223757 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06263361 | Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma. | Background |
Source ClinicalTrials.gov
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8896625 | Rapidly progressive dementia caused by nonenhancing primary lymphoma of the central nervous system. | AJNR Am J Neuroradiol | 1996 | https://conductscience.org/library/papers/8896625 | PubMed |
| 2 | 19186405 | Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. | Neoplasia | 2009 | https://conductscience.org/library/papers/19186405 | PubMed |
| 3 | 22228634 | Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22228634 | PubMed |
| 4 | 27502247 | MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. | Neuro Oncol | 2017 | https://conductscience.org/library/papers/27502247 | PubMed |
| 5 | 22711606 | Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. | Neuro Oncol | 2012 | https://conductscience.org/library/papers/22711606 | PubMed |
| 6 | 18287338 | The utility of body FDG PET in staging primary central nervous system lymphoma. | Neuro Oncol | 2008 | https://conductscience.org/library/papers/18287338 | PubMed |
| 7 | 29848919 | Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient. | Magn Reson Med Sci | 2019 | https://conductscience.org/library/papers/29848919 | PubMed |
| 8 | 28379322 | International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). | Ann Oncol | 2017 | https://conductscience.org/library/papers/28379322 | PubMed |
| 9 | 28640701 | Primary CNS Lymphoma. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28640701 | PubMed |
| 10 | 30033836 | Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. | Leuk Lymphoma | 2019 | https://conductscience.org/library/papers/30033836 | PubMed |
| 11 | 22322605 | The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. | AJNR Am J Neuroradiol | 2012 | https://conductscience.org/library/papers/22322605 | PubMed |
| 12 | 26250565 | Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/26250565 | PubMed |
| 13 | 1552337 | Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. | J Nucl Med | 1992 | https://conductscience.org/library/papers/1552337 | PubMed |
| 14 | 20602148 | Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions. | J Neurooncol | 2011 | https://conductscience.org/library/papers/20602148 | PubMed |
| 15 | 32048719 | Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/32048719 | PubMed |
| 16 | 15955902 | Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15955902 | PubMed |
| 17 | 27666608 | Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor. | Eur J Radiol | 2016 | https://conductscience.org/library/papers/27666608 | PubMed |
| 18 | 8524024 | MR contrast due to intravascular magnetic susceptibility perturbations. | Magn Reson Med | 1995 | https://conductscience.org/library/papers/8524024 | PubMed |
| 19 | 17406788 | Angiogenesis in primary central nervous system lymphoma (PCNSL). | J Neurooncol | 2007 | https://conductscience.org/library/papers/17406788 | PubMed |
| 20 | 22936096 | Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. | AJNR Am J Neuroradiol | 2013 | https://conductscience.org/library/papers/22936096 | PubMed |
Cited by105
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 147 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42823715 | Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics. | Biomark Res | 2026 | https://conductscience.org/library/papers/42823715 | PubMed |
| 42814177 | Primary central nervous system lymphoma in the molecular era: genomic drivers, liquid biopsy, and targeted therapeutic strategies. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42814177 | PubMed |
| 42756914 | Clinical trial design for primary brain tumors: a problem-based framework for neuro-oncology practice. | Front Oncol | 2026 | https://conductscience.org/library/papers/42756914 | PubMed |
| 42741313 | Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta-analysis and systematic review of 1,388 patients. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42741313 | PubMed |
| 42490843 | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System and Systemic Classic Hodgkin Lymphoma in the Same Patient. | J Hematol | 2026 | https://conductscience.org/library/papers/42490843 | PubMed |
| 42453186 | Primary central nervous system lymphoma-current standards and recent developments. | Neurooncol Pract | 2026 | https://conductscience.org/library/papers/42453186 | PubMed |
| 42444831 | Preoperative phenotypic stratification of primary central nervous system lymphoma using multiparametric MRI-based radiomics: prediction of germinal center B-cell-like and double-expression status. | Front Oncol | 2026 | https://conductscience.org/library/papers/42444831 | PubMed |
| 42410107 | Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas. | J Neurol | 2026 | https://conductscience.org/library/papers/42410107 | PubMed |
| 42359975 | Modern Cyanine Dye-Based Photosensitizers for Medical Applications. | Angew Chem Int Ed Engl | 2026 | https://conductscience.org/library/papers/42359975 | PubMed |
| 42339340 | Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma. | Hemasphere | 2026 | https://conductscience.org/library/papers/42339340 | PubMed |
| 42265756 | CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib-Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET-CT. | Am J Hematol | 2026 | https://conductscience.org/library/papers/42265756 | PubMed |
| 42213292 | Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42213292 | PubMed |
| 42129311 | Central nervous system complications after allogeneic haematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee on epidemiology, outcome and neuroimaging. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/42129311 | PubMed |
| 42101313 | Neurolymphomatosis: A Comprehensive Review of Clinical and Imaging Features. | Radiol Imaging Cancer | 2026 | https://conductscience.org/library/papers/42101313 | PubMed |
| 42056569 | CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/42056569 | PubMed |
| 41999193 | Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma. | Int J Cancer | 2026 | https://conductscience.org/library/papers/41999193 | PubMed |
| 41843467 | Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study. | Blood | 2026 | https://conductscience.org/library/papers/41843467 | PubMed |
| 41785308 | Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma. | Blood Adv | 2026 | https://conductscience.org/library/papers/41785308 | PubMed |
| 41696494 | Time matters: The prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma-a single-center, retrospective real-world study. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/41696494 | PubMed |
| 41681925 | The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681925 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CXCL13 | 10563 | PubTator's text mining | https://conductscience.org/library/genes/10563 | NCBI Gene |
| FLT1 | 2321 | PubTator's text mining | https://conductscience.org/library/genes/2321 | NCBI Gene |
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IRF4 | 3662 | PubTator's text mining | https://conductscience.org/library/genes/3662 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33560416
GET https://conductscience.org/api/papers/v1/33560416/authors?page=2